SCHEMBL761434

SCHEMBL761434

C[Si](C)(C)c1ccc(N(c2ccc(-c3ccccc3)cc2)c2ccc3c(-c4ccccc4-c4ccccc4)c4cc(N(c5ccc(-c6ccccc6)cc5)c5ccc([Si](C)(C)C)cc5)ccc4c(-c4ccccc4-c4ccccc4)c3c2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPT P10636 2/20 0.32
MAPK1 P28482 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
NPY1R P25929 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GPR84 Q9NQS5 1/20 0.30
USP2 O75604 1/20 0.30
CTNNB1 P35222 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL761402 0.96 PTAFR (0.32) PTAFRMEN1KMT2AALDH1A1KDM4E
SCHEMBL762127 0.92 PTAFR (0.33) PTAFRMEN1KMT2AALDH1A1KDM4E
SCHEMBL760861 0.89 ACHE (0.33) PTAFRMEN1KMT2AALDH1A1KDM4E
SCHEMBL14516040 0.89 ACHE (0.33) PTAFRMEN1KMT2AALDH1A1KDM4E
SCHEMBL14516043 0.89 ACHE (0.33) PTAFRMEN1KMT2AALDH1A1KDM4E
SCHEMBL760840 0.88 TDP1 (0.33) PTAFRMEN1KMT2AALDH1A1KDM4E
SCHEMBL762139 0.88 ALDH1A1 (0.36) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL1103705 0.87 L3MBTL1 (0.36) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL14515982 0.86 TDP1 (0.33) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL761302 0.86 ENPP1 (0.38) ALDH1A1KDM4EHSD17B10MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902013-B1 NOVEL ANTHRACENE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND ORGANIC ELECTRONIC LIGHT EMITTING DEVICE USING THE SAME LG CHEMICAL LTD (KR) 2016-06-01 EP disclosed
US-8137823-B2 Anthracene derivatives, process for preparation thereof, and organic electronic light emitting device using the same LG CHEM, LTD. (KR) 2012-03-20 US disclosed
US-20090079334-A1 Novel Anthracene Derivatives, Process for Preparation Thereof, and Organic Electronic Light Emitting Device Using the Same LG CHEM, LTD. (KR) 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090079334-A1 Novel Anthracene Derivatives, Process for Preparation Thereof, and Organic Electronic Light Emitting Device Using the Same XPOT, ALAD, APRT PTAFR 4759/4885MEN1 1736/4885KMT2A 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.